Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy_West China Medical Journal

Authors：

 GAOLi ,  FANGXiang-ming , YEWen-chun , HUANGJing , WANGYu-rong

Department of Endocrinology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P. R. China;

Corresponding?author：

FANGXiang-ming, Email: fsm2002@sina.com

Keywords：

Type-2 diabetes mellitus; Diabetic peripheral neuropathy; Pancreatic kinionogenase enteric-coated tab; Methylcobalamin injection; Nerve conduction velocity

DOI：

10.7507/1002-0179.20140441

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the effect of combined treatment using pancreatic kinionogenase enteric-coated tab and mecobalamin injection on diabetic peripheral neuropathy (DPN) patients. Methods We collected 84 subjects with DPN who received treatment from January 2012 to December 2012 in our hospital, and we randomly divided them into treatment group (42 subjects, using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection) and control group (42 subjects, using mecobalamine only). Subjects in the treatment group were given oral pancreatic kininogenase at 120 unit/times and 3 times/day, and methylcobalamin intravenous injection at 1 mg/day for 14 days. Subjects in the control group were only given methylcobalamin intravenous injection at 1 mg/day for 14 days. Results In the treatment group, 22 subjects showed excellent, 19 subjects effective and 1 subject ineffective outcome. In the control group, 8 subjects showed excellent, 22 effective and 12 ineffective outcome. The difference between the two groups is statistically significant (P<0.01). Compared with no treatment, the nerve conduction velocity in both the two groups has been improved. The improvement in the treatment group is significantly better than that of the control group (P<0.01), and all of them had no obvious adverse reaction during the treatment. Conclusion The combined treatment using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection on DPN is better than using methylcobalamin only.

Citation： GAOLi, FANGXiang-ming, YEWen-chun, HUANGJing, WANGYu-rong. Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy. West China Medical Journal, 2014, 29(8): 1432-1434. doi: 10.7507/1002-0179.20140441 Copy

1.	姚合斌, 潘長玉, 陸思珍, 等. 激肽系統在實驗性糖尿病腎病發展中的作用研究[J]. 中國糖尿病雜志, 2000, 8(6):356-359.
2.	Little AA, Edwards JL, Feldman EL. Diabetic neuropathies[J]. Pract Neurol, 2007, 7(2):82-92.
3.	任麗平, 姜喆, 趙穎, 等. 怡開治療30例糖尿病腎病臨床分析[J]. 長春中醫學院學報, 2004, 20(1):13.
4.	張華珍, 蘇言輝, 陳秋. 銀杏達莫聯合甲鈷胺治療糖尿病周圍神經病變的臨床分析[J]. 中國綜合臨床, 2010, 26(4):383-385.
5.	傅漢菁, 袁申元. 胰激肽原酶在糖尿病治療中的臨床應用[J]. 中國實用內科雜志, 2004, 24(11):698-700.
6.	Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy[J]. Diabetes Educ, 2007, 33(1):111-117.
7.	American Diabetes Association. Implication of the United Kingdom prospective diabetes study[J]. Diabetes Care, 1998, 21(12):2180-2184.
8.	柴偉棟, 陳家偉. 微循環與糖尿病微血管病變[J]. 中國微循環, 2000, 4(2):130-132.
9.	KawamuraM, OharaH, GoK, et al. Newrotropini ndues antinociceptive effet by enbancing descending pain inhibitory systems involving 5-HT 3 and nora-drenergic alpha 2 receptors in spinal dorsal horn[J]. Life Sci, 1998, 62(11):2181.
10.	Hotta N, Koh N, Sakakibara F, et al. Neurotropin prevents neurophysiological abnormalities and ADP-induced hyperaggregability in rats with streptozotocin-induced diabetes[J]. Life Sci, 1995, 57(23):2101-2111.
11.	王穎, 丁顏. 彌可保改善糖尿病周圍神經病變療效觀察[J]. 中國醫師雜志, 2002, 4(9):1028-1028.
12.	范本. 依帕司他治療早期糖尿病腎病36例療效觀察[J]. 山東醫藥, 2011, 51(29):95-96.
13.	韓隆元. 硫辛酸與依帕司他聯合門冬胰島素30治療2型糖尿病周圍神經病變療效觀察[J]. 中國醫藥, 2012, 7(2):163-165.
14.	李建波, 陳家偉. 糖尿病神經病變的發病機理及其現代認識[J]. 實用糖尿病雜志, 1997, 5(1):3-5.
15.	孟柳, 朱筠. 2型糖尿病周圍神經病變與血清TAOC、MDA、SOD相關性研究[J]. 實用糖尿病雜志, 2011, 7(5):18-19.
16.	王桂俠, 李廣仁, 劉立, 等. 糖尿病周圍神經病變患者神經病理及臨床研究[J]. 中風與神經疾病雜志, 2000, 17(5):277-279.

1. 姚合斌, 潘長玉, 陸思珍, 等. 激肽系統在實驗性糖尿病腎病發展中的作用研究[J]. 中國糖尿病雜志, 2000, 8(6):356-359.
2. Little AA, Edwards JL, Feldman EL. Diabetic neuropathies[J]. Pract Neurol, 2007, 7(2):82-92.
3. 任麗平, 姜喆, 趙穎, 等. 怡開治療30例糖尿病腎病臨床分析[J]. 長春中醫學院學報, 2004, 20(1):13.
4. 張華珍, 蘇言輝, 陳秋. 銀杏達莫聯合甲鈷胺治療糖尿病周圍神經病變的臨床分析[J]. 中國綜合臨床, 2010, 26(4):383-385.
5. 傅漢菁, 袁申元. 胰激肽原酶在糖尿病治療中的臨床應用[J]. 中國實用內科雜志, 2004, 24(11):698-700.
6. Foster TS. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy[J]. Diabetes Educ, 2007, 33(1):111-117.
7. American Diabetes Association. Implication of the United Kingdom prospective diabetes study[J]. Diabetes Care, 1998, 21(12):2180-2184.
8. 柴偉棟, 陳家偉. 微循環與糖尿病微血管病變[J]. 中國微循環, 2000, 4(2):130-132.
9. KawamuraM, OharaH, GoK, et al. Newrotropini ndues antinociceptive effet by enbancing descending pain inhibitory systems involving 5-HT 3 and nora-drenergic alpha 2 receptors in spinal dorsal horn[J]. Life Sci, 1998, 62(11):2181.
10. Hotta N, Koh N, Sakakibara F, et al. Neurotropin prevents neurophysiological abnormalities and ADP-induced hyperaggregability in rats with streptozotocin-induced diabetes[J]. Life Sci, 1995, 57(23):2101-2111.
11. 王穎, 丁顏. 彌可保改善糖尿病周圍神經病變療效觀察[J]. 中國醫師雜志, 2002, 4(9):1028-1028.
12. 范本. 依帕司他治療早期糖尿病腎病36例療效觀察[J]. 山東醫藥, 2011, 51(29):95-96.
13. 韓隆元. 硫辛酸與依帕司他聯合門冬胰島素30治療2型糖尿病周圍神經病變療效觀察[J]. 中國醫藥, 2012, 7(2):163-165.
14. 李建波, 陳家偉. 糖尿病神經病變的發病機理及其現代認識[J]. 實用糖尿病雜志, 1997, 5(1):3-5.
15. 孟柳, 朱筠. 2型糖尿病周圍神經病變與血清TAOC、MDA、SOD相關性研究[J]. 實用糖尿病雜志, 2011, 7(5):18-19.
16. 王桂俠, 李廣仁, 劉立, 等. 糖尿病周圍神經病變患者神經病理及臨床研究[J]. 中風與神經疾病雜志, 2000, 17(5):277-279.

West China Medical Journal

Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content